Rapport Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
RAPP$25.96-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statement of Stockholders’ Equity
(In thousands, except share data)
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · Total | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Stockholders’ Equity | |
| Balance at December 31, 2025 | 47,772,567 | $48 | $719,287 | $546 | $(235,228) | $484,653 |
| Stock-based compensation expense | — | — | 6,963 | — | — | 6,963 |
| Issuance of common stock upon exercise of stock options | 80,867 | — | 809 | — | — | 809 |
| Vesting of restricted stock units | 6,994 | — | — | — | — | — |
| Repurchase of unvested restricted common stock | (52,975) | — | (5) | — | — | (5) |
| Net loss | — | — | — | — | (19,857) | (19,857) |
| Change in unrealized gain (loss) on investments, net of tax | — | — | — | (1,051) | — | (1,051) |
| Balance at March 31, 2026 | 47,807,453 | $48 | $727,054 | $(505) | $(255,085) | $471,512 |
| Stock-based compensation expense | — | — | 7,202 | — | — | 7,202 |
| Issuance of common stock upon exercise of stock options | 147,626 | — | 1,592 | — | — | 1,592 |
| Net loss | — | — | — | — | (56,615) | (56,615) |
| Change in unrealized gain (loss) on investments, net of tax | — | — | — | (765) | — | (765) |
| Balance at June 30, 2026 | 47,955,079 | $48 | $735,848 | $(1,270) | $(311,700) | $422,926 |
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · Total | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Stockholders’ Equity | |
| Balance at December 31, 2024 | 36,580,202 | $37 | $429,657 | $(522) | $(123,745) | $305,427 |
| Stock-based compensation expense | — | — | 4,040 | — | — | 4,040 |
| Issuance of common stock upon exercise of stock options | 3,240 | — | 6 | — | — | 6 |
| Repurchase of unvested restricted common stock | (86,008) | — | (1) | — | — | (1) |
| Net loss | — | — | — | — | (24,063) | (24,063) |
| Change in unrealized gain (loss) on investments, net of tax | — | — | — | 427 | — | 427 |
| Balance at March 31, 2025 | 36,497,434 | $37 | $433,702 | $(95) | $(147,808) | $285,836 |
| Stock-based compensation expense | — | — | 4,389 | — | — | 4,389 |
| Issuance of common stock upon exercise of stock options | 243 | — | — | — | — | — |
| Net loss | — | — | — | — | (26,732) | (26,732) |
| Change in unrealized gain (loss) on investments, net of tax | — | — | — | 19 | — | 19 |
| Balance at June 30, 2025 | 36,497,677 | $37 | $438,091 | $(76) | $(174,540) | $263,512 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.